Innovative stem cell technologies have potential to treat  Alzheimer’s disease.

https://www.dimensionsdance.org/pack/7226-erectile-disfunction-viagra-cialys-pill.html cialis online pharmacy no prescription watch https://phcoct.org/viagra-femenina-maca/ http://www.salganyc.org/6840-free-viagra-next-day-delivered/ get link ap us history essay questions cheapest essay writing service uk structure writing essay upsr english paper 1 questions cialis en ligne france saint augustine essay follow site need a paper written now how do i know what processor is in my ipad generic viagra 24 hours delivery https://ml4t.org/blog/writing-cause-and-effect-essays/99/ buy cheap viagra online usa how to find case studies acknowledgements dissertation http://biointegrity.org/viagra-in-prison/ creative writing supplement harvard horrible headache from viagra click Today, there is no cure for Alzheimer’s disease and dementia. In 2015, dementia affected more than 46.8 million people worldwide, according to Alzheimer’s Disease International, and an estimated 60-80 percent of those patients have Alzheimer’s disease. The number of dementia cases is expected to grow to 74.7 million in 2030 and to reach 131.5 million in 2050. Stemedica International is the only company to leverage three patented, stem cell technologies (itMSCs, itNSCs and related growth factors) for therapies that may be able to address the global, unmet need for treatments of degenerative conditions, including Alzheimer’s disease and vascular dementia. Stemedica International is also exploring opportunities to prevent the condition, based on promising pre-clinical data.

Stemedica International is using cGMP allogeneic stem cells derived from healthy adult volunteers in clinical trials. Manufactured in a licensed facility under cGMP conditions, the company has successfully completed the safety phase of a clinical trial.